Context
TED, thyroid eye disease, proptosis
THYROID EYE DISEASE, PROPTOSIS, CHRONIC DISEASE
Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.